CTSH Stock Recent News

Fourth quarter revenue of $5.1 billion increased 6.8% year-over-year or 6.7% in constant currency1, at the high end of our guidance range Full-year revenue of $19.7 billion increased 2.0% year-over-year or 1.9% in constant currency Full-year operating margin of 14.7% increased 80 basis points year-over-year; Adjusted Operating Margin1 of 15.3% increased 20 basis points year-over-year Trailing 12-month bookings of $27.1 billion, up 3% year-over-year, driven by 11% year-over-year fourth quarter bookings growth $1.2 billion returned to shareholders through share repurchases and dividends in 2024 Cash dividend increased 3% to $0.31 per share for Q1 2025 2025 revenue growth guidance of 3.5% to 6.0% in constant currency 2025 Adjusted Operating Margin guidance of 15.5% to 15.7%, expansion of 20 to 40 basis points TEANECK, N.J. , Feb. 5, 2025 /PRNewswire/ -- Cognizant (Nasdaq: CTSH), one of the world's leading professional services companies, today announced its fourth quarter and full-year 20

CTSH's fourth-quarter performance is likely to have reflected strength from an expanding clientele and a robust pipeline that includes a favorable mix of new opportunities.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cognizant (CTSH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Cognizant (CTSH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to reveal his favorite stocks in the market.

The organizations plan to support clients through expanded partnership and offer broader access to Medidata's AI-powered technologies to accelerate clinical trial development TEANECK, N.J. , Jan. 30, 2025 /PRNewswire/ -- Cognizant (Nasdaq: CTSH) announced an expanded agreement with Medidata, a Dassault Systèmes brand and leader of clinical trial solutions to the life sciences industry, to provide support for Medidata's life sciences clients and expand the strategic alliance partnership.

Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value TEANECK, N.J. , Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as it advances innovations to prevent and treat life-threatening diseases.

Cognizant (CTSH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MCD stock is set to gain from the renewal of its partnership with Cognizant. Dive in to know more about its strategic collaboration and offerings.

CTSH extends its partnership with McDonald's to enhance staff enablement, customer experience, and operational efficiency using advanced technology.